CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma

Johnson & Johnson received a positive CHMP recommendation from the European Medicines Agency for an indication extension of TECVAYLI® (teclistamab) in combination with daratumumab for relapsed/refractory multiple myeloma treatment. This regulatory milestone represents a meaningful validation of the company's oncology pipeline and expands the addressable market for this novel immunotherapy combination.

The clinical data supporting this recommendation demonstrates statistically significant improvements in both progression-free survival and overall survival versus standard of care, with an 83% three-year survival rate. These Phase 3 results position the combination therapy as a potential new standard of care when administered as early as second-line treatment, suggesting substantial clinical value and differentiation in a competitive multiple myeloma segment.

Regulatory approval in Europe, pending final EMA clearance, would unlock revenue contribution in a large patient population and strengthen JNJ's competitive positioning in oncology—a key growth engine for the company. The indication extension also reinforces confidence in the molecule's safety and efficacy profile across treatment sequences.

Sector implication: This development is positive for large-cap pharmaceutical companies with diversified oncology portfolios and implies continued strength in specialty biopharmaceuticals. The validation of immunotherapy combinations may also elevate investor confidence in broader pipeline assets within Health Care, particularly those targeting hematologic malignancies.